Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392906 | 1.00 | ALOX15 (0.39) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL1970042 | 0.81 | ANPEP (0.48) | BMP1ANPEPENPEP | |
| SCHEMBL7213193 | 0.81 | ALOX15 (0.40) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL7352206 | 0.80 | DPP4 (0.38) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL11363514 | 0.80 | DPP4 (0.38) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL3075720 | 0.78 | — | — | |
| SCHEMBL6039517 | 0.78 | — | — | |
| SCHEMBL9545378 | 0.78 | — | — | |
| SCHEMBL21724570 | 0.76 | CTSD (0.39) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL2246163 | 0.75 | CTSC (0.37) | ALOX15BLMPMP22KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | claimed |
| EP-1818340-A1 | GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES | National University Corporation Nagoya University (JP) | 2007-08-15 | — | — | EP | claimed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8481696-B2 | Glycosylated glycopeptide antibiotic derivatives | SHIONOGI & CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| EP-2314599-A1 | Glycopeptide antibiotic monomer derivatives | National University Corporation Nagoya University (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2233495-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1818340-A1 | GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES | National University Corporation Nagoya University (JP) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | CSGALNACT1, OGT, GALNT1 | ALOX15 3576/4885BLM 4103/4885PMP22 4474/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | ALOX15 4615/4885BLM 4169/4885PMP22 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.